Boehringer Ingelheim and HeartBeat.bio have entered into a research collaboration to develop gene therapy-based treatments for genetic cardiomyopathies
The partnership combines Boehringer’s expertise in gene therapy drug development with HeartBeat.bio’s proprietary Cardioid Drug Discovery Platform, aiming to advance innovative therapies for inherited heart muscle diseases.
HeartBeat.bio’s platform uses chamber-like cardiac organoids derived from induced pluripotent stem cells (iPSCs) to replicate key features of inherited heart diseases. The platform has demonstrated translational relevance in pilot studies, including its applicability for adeno-associated virus (AAV) pharmacological experiments.
Boehringer previously contributed to the development of HeartBeat.bio’s platform by providing R&D expertise, shaping disease-relevant screening assays, and supplying benchmark compounds for validation.
Austria-based HeartBeat.bio, founded in 2021, is advancing its own therapeutic pipeline while partnering with pharma companies to co-develop heart failure treatments. Initial focus areas include cardiomyopathies, myocardial fibrosis, and its effects on cardiac remodeling, a chronic disease phenotype prevalent in most heart failure patients.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!